You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

de Bie, Charlotte I. MD1; Escher, Johanna C. MD, PhD1; de Ridder, Lissy MD, PhD1,*

Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21871
Clinical Reviews
Abstract

Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor‐α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti‐TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD). Nevertheless, adalimumab and certolizumab have been used off‐label to treat refractory pediatric IBD. Over the past 10 years, anti‐TNF treatment has been of great benefit to many pediatric IBD patients, but their use is not without risks (infections, autoimmune diseases, malignancies). Despite the growing experience with these drugs in children with IBD, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of anti‐TNF drugs in pediatric IBD and to discuss the yet‐unsolved issues. (Inflamm Bowel Dis 2011;)

Author Information

1 Department of Pediatric Gastroenterology, Erasmus MC‐Sophia Children's Hospital, Rotterdam, the Netherlands

* Erasmus MC‐Sophia Children's Hospital, Pediatric Gastroenterology, Department of Pediatrics, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, the Netherlands

Email: l.deridder@erasmusmc.nl

Received 12 July 2011; Accepted 29 July 2011

Published online 20 September 2011 in Wiley Online Library (wileyonlinelibrary.com).

Conflict of interest: the second and last author have participated in the REACH study by inclusion of patients (initiated by Centocor). The company did not play any role in the writing of this article.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.